Clinical Trial Update: Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This Clinical Trial Update describes an ongoing Phase 1 study evaluating the safety and tolerability of ziftomenib in combination regimens for relapsed/refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with Npm1 Mutation

Drugs mentioned

• Ziftomenib (ziftomenib)

Snippet

Sponsor: Kura Oncology, Inc. | Conditions: AML, AML With Mutated NPM1 | Phase 1 | Status: RECRUITING